榴莲视频

However, questions remain about durability of vaccine protection, expert says

With few exceptions, treatment can be shortened to 7 days, researcher says

Clesrovimab reduced severe disease, hospitalizations in preterm and term healthy infants

"We have no current effective therapies," for mpox, expert warns

New analysis of Moderna's COVE trial looked at best time for boosters

Trials meet all primary aims, poising them to advance toward clinical use

Use of cefepime meanwhile resulted in more neurological dysfunction

One dose proved noninferior to triple-dose regimen in randomized trial

Antiviral protected older at-risk patients, but appeared to increase risk in teens

And second dose after 1 year appeared to add no extra protection

Findings may encourage increased pediatric vaccine uptake, researcher says

Association strongest with exclusive breastfeeding

Delabeling strategy carries little risk, needs minimal testing, and no specialist consult

While not quite as sensitive as saliva PCR testing, dried blood spot testing has promise